Active/Enrolling:
None at this time; please check back soon.
Closed to Enrollment:
None at this time; please check back soon.
Pending:
None at this time; please check back soon.
Completed:
DOTS
- Principal Investigator: Gary Wang, MD, PhD
- Link: https://clinicaltrials.gov/study/NCT04775953
- Purpose: The goal of DOTS is to compare dalbavancin to standard of care antibiotics for the treatment of patients with complicated S. aureus bacteremia. Patients will be randomized to receive either standard of care antibiotic therapy or dalbavancin.
- Contact: Alexandra Taylor, 352-294-5481, alexandra.taylor@medicine.ufl.edu
DiSArm
- Principal Investigator: Gary Wang, MD, PhD
- Link: https://clinicaltrials.gov/study/NCT05184764
- Purpose: With antibiotic resistance rising, the treatment of bloodstream infections has become more difficult. DiSArm aims to evaluate intravenous AP-SA02, a treatment containing lytic phages that target S. aureus. Patients in this study will be randomized in a 2:1 ratio to receive AP-SA02 or placebo while still receiving standard of care.
- Contact: Tanay Parwal, 314-494-9408, tanay.parwal@medicine.ufl.edu
Mino-Lok
- Principal Investigator: Gary Wang, MD, PhD
- https://clinicaltrials.gov/ct2/show/NCT02901717
- Hospitalized patients with a catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) typically find that the source of the infection is the lumen of their central venous catheter (CVC). The Mino-Lok study seeks to evaluate the safety and efficacy of Mino-Lok Therapy (MLT) in combination with standard of care antibiotics for treatment of hospitalized patients with CRBSIs and CLABSIs. Patients in this study will be randomized to one of two arms, a MLT arm or a Control Arm receiving antibiotic lock therapy.
- Contact: Alexandra Taylor, 352-294-5481, alexandra.taylor@medicine.ufl.edu.